ArticlePloS one2025
Association of ABCG2 421G>T (rs2231142) Polymorphism with rosuvastatin induced adverse effects in dyslipidemic patients: Implication for personalized medicine.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacogenomics of treatment toxicities in pediatric B-Cell ALL: toward safer precision therapy.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins are considered as the first line drugs for the treatment of hyperlipidemia. Despite proven efficacy of rosuvastatin, inter-individual variations in plasma rosuvastatin levels have been documented in various studies which causes variable response to statin tolerance. This study aims to evaluate the possible association of ABCG2 421 G > T (rs2231142) polymorphism with inter-individual variations in plasma rosuvastatin levels which potentially increases the rosuvastatin related adverse effects. This quasi experimental study was carried out from June 2022 till December 2023 in two tertiary care hospitals of Pakistan. Hyperlipidemic patients with low density lipoprotein more than 130 mg/dl were enrolled through non-probability purposive sampling. All the enrolled patients were treated with rosuvastatin 10 mg once daily for 12 weeks. Fasting lipid profile, serum creatine phosphokinase, liver and renal function tests were measured at the start of study and after 12 weeks of intervention with rosuvastatin. Blood samples were also collected for genotyping and determination of plasma rosuvastatin levels. Frequency of ABCG2 421 G > T polymorphism for wild type GG, heterozygous mutant GT and homozygous mutant TT genotypes were 54.5, 36.2 and 9.3% respectively. Minor allele frequency was 0.27. Patients with TT and GT genotypes have significantly raised plasma levels of rosuvastatin with mean value of 30.23 ± 4.8 ng/mL and 22.35 ± 5.1 ng/mL respectively as compared to wild GG genotypes 13.95 ± 8.9 ng/mL (p=<0.001). Frequency of myopathy, hepatotoxicity and nephrotoxicity in study population was 5.3, 3.2 and 4.8% respectively. All the genetic models including co-dominant model GT (OR= 5.45, 95% CI: 3.09-9.62, p= < 0.0001), TT (OR= 88.51, 95% CI: 24.84-315.44), dominant model (OR= 8.45, 95% CI: 4.91-14.52, p= < 0.0001), recessive model (OR=37.29, 95%CI 11.06-125.78, p < 0.001), over-dominant model, (OR= 2.26, 95% CI: 1.42-3.60, p= < 0.0001) showed significant association with rosuvastatin adverse effects. It is inferred that patients having T variant allele is associated with higher plasma rosuvastatin concentration and increased the risk of development of adverse effects compared with G allele carriers. It is therefore suggested that genetic profiling may be done for dose tailoring to minimize the statin intolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.